A Phase I, Open Label, Randomized, Three Period, One-Way, Two Cohort, Adaptive Crossover Study to Evaluate the Effect of Darunavir/Ritonavir Plus Etravirine and Lopinavir/Ritonavir Plus Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING112934).

Trial Profile

A Phase I, Open Label, Randomized, Three Period, One-Way, Two Cohort, Adaptive Crossover Study to Evaluate the Effect of Darunavir/Ritonavir Plus Etravirine and Lopinavir/Ritonavir Plus Etravirine on GSK1349572 Pharmacokinetics in Healthy Adult Subjects (ING112934).

Completed
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2012

At a glance

  • Drugs Darunavir; Dolutegravir; Etravirine; Lopinavir/ritonavir; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 Feb 2012 Company added in association field as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual patient number (17) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top